Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; purified talc; lactose monohydrate; hypromellose; titanium dioxide; magnesium stearate; hyprolose; macrogol 6000; croscarmellose sodium - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; povidone; titanium dioxide; hypromellose; macrogol 4000 - ? for the treatment of hypertension. ? for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; microcrystalline cellulose; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - ? for the treatment of hypertension. ? for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; lactose monohydrate; titanium dioxide; macrogol 4000 - - indicated for the treatment of hypertension.,- indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 4000 - - indicated for the treatment of hypertension.,- indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: mannitol; crospovidone; povidone; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; purified water; titanium dioxide; hypromellose; macrogol 400 - for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; magnesium stearate; povidone; titanium dioxide; hypromellose; macrogol 4000 - irbesartan is indicated for the following: for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan is indicated for the following: for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; povidone; microcrystalline cellulose; magnesium stearate; hydrogenated castor oil; maize starch; lactose monohydrate - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; povidone; hydrogenated castor oil; maize starch; magnesium stearate; lactose monohydrate; croscarmellose sodium - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.